These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31767510)

  • 21. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder.
    Abdel-Baki A; Thibault D; Medrano S; Stip E; Ladouceur M; Tahir R; Potvin S
    Early Interv Psychiatry; 2020 Feb; 14(1):69-79. PubMed ID: 31125513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evaluation and treatment of first-episode psychosis.
    Sheitman BB; Lee H; Strous R; Lieberman JA
    Schizophr Bull; 1997; 23(4):653-61. PubMed ID: 9366001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement in verbal learning over the first year of antipsychotic treatment is associated with serum HDL levels in a cohort of first episode psychosis patients.
    Gjerde PB; Simonsen CE; Lagerberg TV; Steen NE; Ueland T; Andreassen OA; Steen VM; Melle I
    Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):49-58. PubMed ID: 31028479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early use of clozapine for poorly responding first-episode psychosis.
    Agid O; Remington G; Kapur S; Arenovich T; Zipursky RB
    J Clin Psychopharmacol; 2007 Aug; 27(4):369-73. PubMed ID: 17632221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders.
    Scheffler F; Kilian S; Chiliza B; Asmal L; Phahladira L; du Plessis S; Kidd M; Murray RM; Di Forti M; Seedat S; Emsley R
    Schizophr Res; 2018 Sep; 199():90-95. PubMed ID: 29519756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The course and concomitants of depression in first-episode schizophrenia spectrum disorders: A 24-month longitudinal study.
    Phahladira L; Asmal L; Lückhoff HK; du Plessis S; Scheffler F; Kilian S; Smit R; Buckle C; Chiliza B; Emsley R
    Psychiatry Res; 2021 Apr; 298():113767. PubMed ID: 33545422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders.
    Phahladira L; Asmal L; Kilian S; Chiliza B; Scheffler F; Luckhoff HK; du Plessis S; Emsley R
    Schizophr Res; 2019 Apr; 206():394-399. PubMed ID: 30385130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.
    Alvarez-Jimenez M; O'Donoghue B; Thompson A; Gleeson JF; Bendall S; Gonzalez-Blanch C; Killackey E; Wunderink L; McGorry PD
    CNS Drugs; 2016 May; 30(5):357-68. PubMed ID: 27106296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis.
    Bowtell M; Eaton S; Thien K; Bardell-Williams M; Downey L; Ratheesh A; Killackey E; McGorry P; O'Donoghue B
    Schizophr Res; 2018 May; 195():231-236. PubMed ID: 29066258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals.
    Velakoulis D; Wood SJ; Wong MT; McGorry PD; Yung A; Phillips L; Smith D; Brewer W; Proffitt T; Desmond P; Pantelis C
    Arch Gen Psychiatry; 2006 Feb; 63(2):139-49. PubMed ID: 16461856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review.
    Bowtell M; Ratheesh A; McGorry P; Killackey E; O'Donoghue B
    Schizophr Res; 2018 Jul; 197():9-18. PubMed ID: 29146020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prescription practices of antipsychotic medication in early psychosis: a two-year follow-up survey of subjects admitted in two psychiatric hospitals of South-Western France].
    Grolleau A; Cougnard A; Parrot M; Kalmi E; Desage A; Misdrahi D; Brun-Rousseau H; Verdoux H
    Encephale; 2007; 33(3 Pt 1):326-31. PubMed ID: 17675930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
    Morlán-Coarasa MJ; Arias-Loste MT; Ortiz-García de la Foz V; Martínez-García O; Alonso-Martín C; Crespo J; Romero-Gómez M; Fábrega E; Crespo-Facorro B
    Psychopharmacology (Berl); 2016 Dec; 233(23-24):3947-3952. PubMed ID: 27620899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial.
    Clausen L; Hjorthøj CR; Thorup A; Jeppesen P; Petersen L; Bertelsen M; Nordentoft M
    Psychol Med; 2014 Jan; 44(1):117-26. PubMed ID: 23590927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.